A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004960-64

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of this study is to assess whether duloxetine hydrochloride 60 to 120 mg once daily (QD) is superior to placebo in the treatment of generalized anxiety disorder (GAD), as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), during a 10-week, double-blind, acute therapy phase. Superiority is defined as statistically greater reduction in the mean change from baseline to endpoint in anxiety symptoms as measured by the Hamilton Anxiety Rating Scale (HAMA) total score (Hamilton 1959).


Critère d'inclusion

  • generalised anxiety disorder